Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer

• Published in: Breast cancer research : BCR Vol. 26; no. 1; pp. 1 - 15
• Main Authors: Du, Jiaqun, Liu, Xiaobang, Sun, Junpeng, Wu, Qian, Hu, Yu, Shi, Huan, Zheng, Li, Liu, Ying, Wu, Chao, Gao, Yu
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 12.06.2024; BioMed Central; BMC
• Subjects: Antibodies; Apoptosis; Biomimetics; Breast cancer; Cancer; Cancer therapies; Cell membranes; Cell proliferation; Chemotherapy; Controlled release; Drug resistance; ErbB-2 protein; Ethylenediaminetetraacetic acid; Flow cytometry; Health aspects; HER2-positive breast cancer; Immunofluorescence; Kinases; Light scattering; Lipids; Liposome; Liposomes; Medical research; Oncology, Experimental; Particle size; Polyacrylamide; Proteins; Pyrotinib; SK-BR-3 cell membranes; Targeted therapy; Transmission electron microscopy; Trastuzumab; Tumor cells; Western blotting; Womens health; Canada; China; Germany; United Kingdom > UK; Beijing China
• ISSN: 1465-5411; 1465-542X; 1465-542X
• DOI: 10.1186/s13058-024-01853-2

In this study, we prepared a bionic nanosystem of trastuzumab-functionalized SK-BR-3 cell membrane hybrid liposome-coated pyrotinib (Ptb-M-Lip-Her) for the treatment of HER2-positive breast cancer. Transmission electron microscopy, dynamic light scattering, polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting were used to verify the successful preparation of Ptb-M-Lip-Her. In vitro drug release experiments proved that Ptb-M-Lip-Her had a sustained release effect. Cell uptake experiments and in vivo imaging experiments proved that Ptb-M-Lip-Her had good targeting ability to homologous tumor cells (SK-BR-3). The results of cell experiments such as MTT, flow cytometry, immunofluorescence staining and in vivo antitumor experiments showed that Ptb-M-Lip-Her could significantly promote apoptosis and inhibit the proliferation of SK-BR-3 cells. These results clearly indicated that Ptb-M-Lip-Her may be a promising biomimetic nanosystem for targeted therapy of HER2-positive breast cancer.